HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kedar, E. Articles by Bonavida, B. Search for Related Content PubMed Articles by Kedar, E. Articles by Bonavida, B.

Histamine Receptor-Bearing Leukocytes (HRL)

I. Detection of Histamine Receptor-Bearing Cells by Rosette Formation with Histamine-Coated Erythrocytes¹

Department of Microbiology and Immunology, University of California School of Medicine, Los Angeles, California 90024

Abstract

A rosette technique is described for the enumeration and identification of histamine receptor-bearing leukocytes (HRL). Mouse leukocytes from a variety of lymphoid tissues form rosettes with sheep erythrocytes coated with histaminerabbit serum albumin (RSA) conjugate. Rosette formation was specifically inhibited by either histamine-RSA or by histamine, but not by RSA. The percentage of rosettes in lymphoid tissues of adult mice ranged from 8% in the thymus to 70% in the peritoneal exudate leukocytes. Spleen, bone marrow, peripheral blood, and lymph node cells produced intermediate numbers of rosettes (20 to 40%).

Spleen and peritoneal exudate leukocytes derived from mice and rats immunized against allogeneic and syngeneic tumors, respectively, demonstrated a significantly lower frequency of HRL as compared with unsensitized cells. The vast majority of immune lymphoblasts, however, exhibited a high degree of rosette formation and were coated heavily with the indicator erythrocytes. Of particular interest was the observation that a number of tumor cells (four leukemias, one mastocytoma, and one plasmacytoma) showed little or no rosette formation.

Footnotes

¹ This investigation was supported by Grant CA 12800 from the National Cancer Institute, National Institutes of Health, Bethesda, Maryland.